TrovaGene (TROV) Receives New Patent for PCM Technology
TrovaGene, Inc. TROV recently announced the receipt of a new patent entitled "Compositions, Methods and Kits for Isolating Nucleic Acids from Body Fluids Using Anion Exchange Media." This takes TrovaGene’s patent count to 87 in the U.S. and international markets.
The new patent includes techniques for quick segregation of systemically derived ctDNA as well as distillation of nucleic acids derived from urine samples using anion exchange media.
The latest patent, issued by the U.S. Patent and Trademark Office, considerably boosts TrovaGene’s intellectual property related to its Precision Cancer Monitoring (PCM) technology. The company notably has 59 issued patents covering its PCM technology and the finding of cell free nucleic acids in bodily fluids.
We believe TrovaGene’s PCM technology is a long-term growth catalyst. The company is focused on introducing and also driving adoption of the platform among tactically selected clinicians and institutions. The benefits of TrovaGene’s PCM platform are quite apparent, with the presentation of positive data at various clinical oncology meetings this year.
This October, the company announced data from a lung cancer study in which the company’s urine-based liquid biopsy platform showed clinical sensitivity of almost 93%. In September, Trovagene presented positive clinical data related to its PCM platform at the 16th World Conference on Lung Cancer and 2015 European Cancer Congress.
The urine-based liquid biopsy platform has been proved to detect EGFR T790M mutations in urinary ctDNA, which can result in better management of the disease. T790M mutations are found in patients who develop resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib.
It is to be noted that TrovaGene’s non-invasive, cell-free technology is cost efficient. We feel that the technology can be ancillary to the current standard of tissue biopsy. It can also be performed in patients not fit for a tissue biopsy. We believe that there is significant market opportunity for TrovaGene as an important player in urine-based liquid biopsy platforms. On the flip side, the technology is relatively at an early stage, which implies that it will take some time before accelerated adoption begins.
Zacks Rank & Other Key Picks
TrovaGene carries a Zacks Rank #2 (Buy).
Other well placed stocks in the medical sector include Masimo MASI, Steris Plc STE and Natus Medical BABY. All the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MASIMO CORP (MASI): Free Stock Analysis Report
NATUS MEDICAL (BABY): Free Stock Analysis Report
STERIS PLC (STE): Free Stock Analysis Report
TROVAGENE INC (TROV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
